Citron On Questcor: Serious Jeopardy for Synacthen Deal – ValueWalk Premium
questcor

Citron On Questcor: Serious Jeopardy for Synacthen Deal

questcorOn June 11, Questcor Pharmaceuticals Inc (NASDAQ:QCOR) surprised the investment community with news that it had acquired rights to Synacthen for the United States and up to 40 countries from Novartis AG (ADR) (NYSE:NVS). Within weeks the stock had doubled on that news, adding 1.75 billion in market cap.  Why?

Simple.  Synacthen is a synthetic version of ACTH, the sole labeled active ingredient in Acthar, which is Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s only source of revenue.  Synacthen has been prescribed in Europe for well over a decade for the same general spectrum of indications that Acthar is labeled for in the US – but at 1/1000th the price.

So when Questcor Pharmaceuticals Inc (NASDAQ:QCOR), which previously had no pipeline, no investigational efforts, and no significant double-blind studies proving efficacy of Acthar vs Synacthen, acquired these rights, the analyst community  went all giddy –  fawning all over how this move protected Questcor’s barrier to competition with regard to the pricing of Acthar.  Questcor postured the deal as if they bought Synacthen just because they wanted to acquire a new drug, but anyone with half a brain knew that was bullshit.

And thank God the FTC has more than half a brain … sorry, Questcor Pharmaceuticals Inc (NASDAQ:QCOR).

Questcor and the FTC Final by ValueWalk.com

LEAVE A COMMENT


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

What’s missing today for many investors is real, straightforward advice.

Especially when it comes to Value Investing and Hedge Funds. 💵

That’s what makes ValueWalk Premium different. Some would say we’re “unusual.”

Our subscribers look forward to clear, easy-to-understand information they can act on.

Sign up for  today for only a few dollars a day and get a 3 day no obligation trial with a targeted 20% discount coupon code.

Cancel anytime during trial and you are never charged.

Limited time offer: For first 50 subscribers

0